Hemostemix Inc.: Hemostemix Announces Private Placement Update
Hemostemix or the
Company ) announces that it was granted price protection of its previously announced non-brokered private placement of units (
Units ) announced on December 18, 2020, for gross proceeds of up to $2,750,000 (the
Offering ). The Offering will consist of the issuance of an aggregate of up to 9,166,666 post rollback Units at a price of $0.30 per Unit. Each Unit consists of one post rollback common share in the capital of the Company (
Common Share ) and one post rollback common share purchase warrant (
Warrant ), with each full Warrant entitling the holder to acquire one Common Share at a price of $1.00 per Common Share for a period of 12 months from the closing of the Offering, subject to the accelerated expiry provision described below.
Calgary, Alberta (Newsfile Corp. - December 23, 2020) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) ("Hemostemix" or the "Company") The Company is pleased to announce that the previously disclosed proposed
Hemostemix Inc.: Hemostemix Announces Closing of Existing Private Placement and Announces a New Private Placement
Hemostemix or the
Units ) for gross proceeds of $1,272,117.04 (the
Offering ). The Offering consisted of the issuance of an aggregate of 127,211,704 Units at a price of $0.01 per Unit. Each Unit consists of one common share in the capital of the Company (
Common Share ) and one common share purchase warrant (
Warrant ), with each full Warrant entitling the holder to acquire one Common Share at a price of $0.05 per Common Share for a period of 12 months from the closing of the Offering, subject to the accelerated expiry provision described below.